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Apicomplexan parasites are the cause of many 
important infectious diseases. These include ma-
laria,  toxoplasmosis,  and  cryptosporidiosis  in 
man and theileriosis, babesiosis, and coccidiosis 
in domestic animals. At this point, no effective 
vaccines are available to prevent diseases caused 
by apicomplexans in humans, and management 
therefore relies on drug treatment. Treatment 
of malaria, in particular, is threatened by the 
rapid emergence of drug-resistant parasites, and 
a constant stream of new drugs with new modes 
of action is required to stay ahead of the patho-
gen. One of the most promising sources for 
new targets is the apicomplexan plastid or apico-
plast (Wiesner et al., 2008). The apicoplast is 
believed to be the remnant of an alga and the 
product of an ancient secondary endosymbiosis 
that gave rise to the super phylum Chromal-
veolata (Gould et al., 2008). Numerous chro-
malveolate groups, such as kelps or diatoms, are 
still photosynthetic, whereas others, like ciliates 
and select apicomplexans, have lost their photo-
synthetic ability and have turned to predation 
or adopted parasitism. Despite the loss of photo-
synthesis, the apicoplast is critical for the sur-
vival  of  apicomplexans.  Pharmacological  and 
genetic  studies  in  Toxoplasma  gondii  and  the 
malaria  parasite  Plasmodium  have  shown  that 
loss of the apicoplast, loss of its genome, or loss 
of its metabolic function result in the death of 
these parasites. The overall picture that has 
emerged over the last decade is that the apico-
plast functions similarly to a chloroplast in the 
dark in that it acts as an anabolic hub providing 
metabolites for the parasite cell (Ralph et al., 
2004; Seeber and Soldati-Favre, 2010). Three 
major anabolic pathways have been identified 
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Apicomplexa are important pathogens that include the causative agents of malaria, toxo-
plasmosis, and cryptosporidiosis. Apicomplexan parasites contain a relict chloroplast, the 
apicoplast. The apicoplast is indispensable and an attractive drug target. The apicoplast is 
home to a 1-deoxy-d-xylulose-5-phosphate (DOXP) pathway for the synthesis of isopren-
oid precursors. This pathway is believed to be the most conserved function of the apico-
plast, and fosmidomycin, a specific inhibitor of the pathway, is an effective antimalarial. 
Surprisingly, fosmidomycin has no effect on most other apicomplexans. Using Toxoplasma 
gondii, we establish that the pathway is essential in parasites that are highly fosmidomycin 
resistant. We define the molecular basis of resistance and susceptibility, experimentally 
testing various host and parasite contributions in T. gondii and Plasmodium. We demon-
strate that in T. gondii the parasite plasma membrane is a critical barrier to drug uptake.  
In strong support of this hypothesis, we engineer de novo drug-sensitive T. gondii parasites by 
heterologous expression of a bacterial transporter protein. Mice infected with these trans-
genic parasites can now be cured from a lethal challenge with fosmidomycin. We propose 
that the varied extent of metabolite exchange between host and parasite is a crucial 
determinator of drug susceptibility and a predictor of future resistance.
© 2011 Nair et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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and this is not feasible or sufficient in other host cell niches. 
This suggests that the importance of a particular anabolic 
pathway depends on the specific host cell infected by the 
parasite and that, therefore, the mere presence of the enzymes 
does not prove their essentiality. Fosmidomycin appears to be 
highly effective against apicomplexans that develop within 
RBCs like Plasmodium and Babesia. Babesia causes a disease 
similar to malaria in cattle and a variety of other mammals.   
in the apicoplast: a type II fatty acid synthesis (FASII) path-
way, a 1-deoxy-d-xylulose-5-phosphate (DOXP) pathway 
for the synthesis of isoprenoid precursors, and a portion of 
the heme biosynthetic pathway. Different apicomplexan par-
asites exhibit marked differences as to which of these path-
ways are present. The most conserved metabolic function of 
the apicoplast appears to be the DOXP pathway, as the genes 
encoding the enzymes for isoprenoid synthesis are thus far 
found in all apicomplexans that harbor an apicoplast.
The DOXP pathway was first discovered in the chloro-
plasts of plants and algae then subsequently identified in eu-
bacteria (Horbach et al., 1993; Lichtenthaler et al., 1997). 
The pathway is also referred to as the nonmevalonate path-
way to highlight its use of an entirely different set of enzymes 
from the classical mevalonate pathway used by animals and 
fungi.  Despite  starting  from  different  substrates,  both  the 
DOXP and the mevalonate pathway converge on one end 
product isopentenyl pyrophosphate (IPP) and its isomer di-
methylallyl pyrophosphate (DMAPP). IPP and DMAPP are 
precursors used to synthesize a wide variety of lipids with 
important functions in membrane structure, protein modifi-
cation, metabolism, and hormone signaling including choles-
terol, dolichol, farnesol, abscisic acid, ubiquinone, modified 
tRNAs, and isopentenylated proteins.
Apicomplexa lack a mevalonate pathway but harbor a 
DOXP pathway in the apicoplast. Because the parasite DOXP 
pathway is mechanistically different from the host mevalo-
nate pathway, it appears to be a promising drug target in api-
complexans, and fosmidomycin—an antibiotic which specifically 
inhibits DOXP reductoisomerase (DOXPRI)—shows robust 
activity against Plasmodium and Babesia in vitro and in animal 
models (Jomaa et al., 1999). Fosmidomycin is also effective in 
the clinical treatment of uncomplicated cases of malaria when 
combined with other drugs that target apicoplast functions 
(Lell et al., 2003). Surprisingly, though, fosmidomycin has no 
effect on the growth of many other members of the phylum 
including Eimeria, Theileria, and T. gondii (Ling et al., 2005; 
Clastre et al., 2007; Lizundia et al., 2009). Nevertheless, ge-
nome mining identifies genes encoding the enzymes of the 
DOXP pathway in these fosmidomycin-insensitive organ-
isms, and expression studies suggest that the genes are actively 
transcribed (Clastre et al., 2007; Moreno and Li, 2008). One 
rationalization for such differential sensitivity is that apico-
plast isoprenoid synthesis might not be as important for para-
site survival as anticipated.
Indeed, not all biosynthetic functions of the apicoplast are 
essential over the entire parasite life cycle. The synthesis of 
fatty acids that occurs in the apicoplast in parallel to the syn-
thesis of isoprenoid precursors has been studied in more detail 
and the findings illustrate this point. Genetic studies revealed 
that apicoplast fatty acid synthesis is essential for T. gondii and 
the initial liver stages of Plasmodium, but surprisingly, this 
pathway was found to be dispensable in the subsequent blood 
phase of the malaria parasite (Mazumdar et al., 2006; Yu et al., 
2008; Vaughan et al., 2009). Apparently the erythrocytic 
stage of the parasite relies entirely on the salvage of fatty acids, 
Figure 1.  T. gondii is resistant to fosmidomycin. (A) Schematic 
representation of apicoplast fatty acid and isoprene biosynthesis path-
ways (highlighted in white). Both pathways depend on substrates im-
ported from the cytoplasm by the APT. Note the structural similarity 
between DOXP and fosmidomycin. Selected enzymes are italicized: PDH, 
pyruvate dehydrogenase; DOXPS, DOXP synthase; ACP acyl carrier pro-
tein. DOXP pathway intermediates: MEP, methylerythritol-phosphate; 
CDP-ME, cytosine dinucleotide phosphate methylerythritol; MEcPP, 
methylerythritol cyclopyrophosphate; HMBPP, hydroxymethy-but-enyl 
pyrophosphate. Apicoplast is shown bounded by a single membrane for 
simplicity. (B) Growth of T. gondii in the presence or absence of fosmido-
mycin (Fos). Fluorescence data are shown as percent of the highest value 
of the untreated control. Data points reflect the mean of duplicate wells 
and error bars show standard deviation. Where no bar is shown it was 
smaller than the symbol. All of the subsequent fluorescence assays are 
shown in this way.JEM Vol. 208, No. 7 
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of T. gondii. We demonstrated that blocking the 
metabolic activity of the apicoplast by ablating car-
bon import through APT results in the rapid de-
mise of the parasite. We further showed that carbon 
import is required for fatty acid synthesis as ex-
pected but, more importantly, that blocking import 
had a more pronounced growth effect than block-
ing just FASII. We took these results as an indica-
tion that the DOXP pathway, which like FASII is 
fed by APT (Fig. 1), should be essential in T. gondii 
and, hence, a promising drug target. This view is 
obviously not supported by the lack of activity of 
fosmidomycin. In this study, we use T. gondii as a 
model organism to resolve this conundrum and 
make  comparisons  with  Plasmodium  in  different 
host cells. We provide unequivocal genetic evi-
dence for the importance of the apicoplast isopren-
oid pathway. We explore several potential molecular 
mechanisms for fosmidomycin resistance and con-
clude that T. gondii is resistant as the result of a lack 
of drug uptake at the level of the parasite cell membrane by en-
gineering a de novo drug-sensitive parasite strain.
RESULTS
T. gondii is resistant to fosmidomycin, but the DOXP 
pathway is nonetheless essential
The DOXP pathway is initiated by the condensation of pyru-
vate and glyceraldehyde-3-phosphate and consists of seven cat-
alytic reactions leading to the synthesis of IPP and DMAPP 
(Fig. 1 A). Fosmidomycin is an inhibitor of the second and 
committing step that is catalyzed by the enzyme DOXPRI. 
Fosmidomycin mimics the substrate DOXP (Fig. 1 A) and 
binds to the active site of the enzyme (Steinbacher et al., 2003). 
In contrast, those apicomplexans that are resistant for fosmid-
omycin parasitize nucleated cells; Theileria infects lympho-
cytes, Eimeria infects epithelial cells, and T. gondii develops in 
macrophages and many other nucleated cell types. One hy-
pothesis could therefore be that isoprenoids are a limiting re-
source in RBCs but can be salvaged from nucleated cells that 
may more vigorously synthesize these compounds and, thus, 
render synthesis by the parasite redundant.
The hypothesis that parasitism of nucleated cells allows iso-
prenoid salvage is contrary to our interpretation of recent exper-
iments tracing the carbon flux into the apicoplast (Brooks et al., 
2010; Lim et al., 2010). In these studies, we constructed a con-
ditional mutant in the apicoplast phosphate translocator (APT) 
Figure 2.  LytB, the terminal step of the DoxP path-
way, is indispensible. (A) Immunofluorescence assay of 
parasites expressing epitope-tagged LytB. Cells were coun-
terstained for the apicoplast protein ACP and DNA (DAPI). 
(B) Southern blot analysis of BglII restricted genomic DNA 
of wild type (RH), LytB parental (iLytB), and conditional 
mutant (LytB) probed with a PCR product representing 
the first exon and intron. The native locus is predicted to 
produce two bands (2.9 and 3.2 kb; see Fig. S2 A for a 
map), and the ectopic-regulated copy is predicted to pro-
duce a single 8-kb fragment. (C) Western blot of protein 
extracts of parasites cultured for 0–3 d under ATc. Both 
pLytB (LytB precursor) and mLytB (mature LytB) were de-
tected using an antibody to the myc epitope tag. Dense 
granule protein 8 (GRA8) serves as loading control.  
(D) Plaque assays comparing the growth of the LytB mu-
tant (LytB) with the parentral line (iLytB) and a mutant 
clone expressing a complementing copy of the gene under 
a constitutive promoter (LytB Comp). (E) Fluorescence 
growth assays for the same parasite lines growing in the 
presence (+ATc) or absence (ATc) of ATc, or after preincu-
bation with ATc (3 d +ATc). Data points reflect the mean of 
duplicate wells and error bars show standard deviation. 
Where no bar is shown it was smaller than the symbol.1550 Fosmidomycin resistance in Toxoplasma gondii | Nair et al.
pathway through metabolite diversion from other pathways 
(Ershov et al., 2002). This shunt renders IPP synthesis resistant 
to fosmidomycin treatment. We therefore considered that the 
final steps of the pathway are required but the early step medi-
ated by DOXPRI is not. To test this, we turned our attention 
to T. gondii DOXPRI directly. Once again, the predicted gene 
model lacked a targeting peptide. We conducted 5 RACE 
experiments and, in this case, identified two additional exons 
5 of the available model (Fig. S2 B). These exons appeared to 
encode a canonical signal peptide followed by a transit peptide 
Previous studies using Eimeria and T. gondii reported resistance 
of both parasites to fosmidomycin (Ling et al., 2005; Clastre et al., 
2007). We confirmed this result. As shown in Fig. 1 B, T. gondii 
growth is normal in the presence of 100 µM of the drug. For 
comparison, the IC50 for Plasmodium falciparum and Babesia 
bovis are 0.4–1.2 and 3–4 µM, respectively (Jomaa et al., 1999; 
Sivakumar et al., 2008). T. gondii has been shown to take up 
isoprenoids in radiolabeling experiments (Ibrahim et al., 2001), 
and the DOXP pathway may therefore be dispensable. To test 
this hypothesis, we constructed a conditional mutant in the 
T. gondii LytB gene. LytB encodes the enzyme 1-hydroxy-2-
methyl-2-(E)-butenyl 4-diphosphate reductase that produces 
IPP and DMAPP in the final step of the DOXP pathway 
(Fig. 1 A). A candidate gene for LytB is readily identified in   
the T. gondii genome by similarity searches (toxoDB gene 
ID TGGT1_082920). The gene appeared not to encode an   
N-terminal signal peptide as typical for apicoplast proteins, but 
we note the presence of a potential recessed signal peptide at aa 
156–179 (a similar presumptive recessed signal is present in the 
P. falciparum homologue). We evaluated the gene prediction 
using 5 RACE PCR, and the sequence of the LytB transcript 
established in our experiments matched the predictions of gene 
model TGGT1_082920. We next engineered an expression 
construct that fused the LytB coding sequence to a C-terminal 
epitope tag and placed it under the control of a tetracycline reg-
ulatable promoter (see Fig. S1 for a schematic outline of the ge-
netic strategy and further detail on the various selection markers 
and promoters used). The construct was transfected into a 
T. gondii transactivator strain (Meissner et al., 2002). Immuno-
fluoroscence staining for the epitope tag was indistinguishable 
from that of the known apicoplast protein ACP, and the pro-
tein was proteolytically processed as typical for apicoplast pro-
teins (Fig. 2, A and C). To establish whether apicoplast IPP 
synthesis is dispensable, we targeted the native LytB locus in this 
strain using a recently developed cosmid-based approach (Brooks 
et al., 2010). Successful gene deletion was confirmed by PCR 
and by Southern blotting (Fig. 2 B and Fig. S2 A). In this mu-
tant strain, the epitope-tagged transgene is the only LytB gene, 
and its expression can be repressed with anhydrotetracycline 
(ATc). Western blot analyses show that after 2 d of treatment 
with ATc, LytB-myc is no longer detectable (Fig. 2 C). We in-
troduced a red fluorescent protein expression cassette into mu-
tant (LytB) and parental strain (iLytB) and measured parasite 
growth by plaque and fluorescence assay (Gubbels et al., 2003). 
Mutant parasites show a severe growth defect in the presence of 
ATc that was not observed in the parental strain. This pheno-
type could be fully rescued by complementing with a LytB 
gene under a constitutive -tubulin promoter, suggesting that 
loss of growth is specific to loss of LytB. We conclude that IPP 
and DMAPP production by the last step of the apicoplast DOXP 
pathway is essential for the T. gondii tachyzoite.
DOXPRI, the target of fosmidomycin, is required  
for parasite growth
The cyanobacterium Synechocystis can, under certain growth 
conditions, negate the necessity for early steps of the DOXP 
Figure 3.  DOXPRI, the target of fosmidomycin, is required for par-
asite growth. (A) Immunofluorescence of a parasite clone expressing a 
myc-tagged DOXPRI under the control of the tubulin promoter. (B) South-
ern blot using the coding sequence of DOXPRI as probe comparing wild 
type (RH), parental (iDOXPRI), and conditional mutant (DOXPRI). Xho1 
restriction of the native locus produces a fragment of 3.8 kb (see Fig. S2 B 
for a map), and the regulatable ectopic locus produces a 0.9-kb fragment. 
(C) Western blot measuring the amount of DOXPRI in the mutant upon 
ATc treatment using an antibody raised against recombinant T. gondii 
DOXPRI. (D and E) Fluorescence (D) or plaque (E) assay measuring the 
growth of mutant and parental strain in the presence or absence of ATc 
(see Fig. 2 E for detail). Fluorescence data points reflect the mean of du-
plicate wells and error bars show standard deviation. Where no bar is 
shown it was smaller than the symbol.JEM Vol. 208, No. 7 
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Overall, these experiments implicate drug accessibility as 
the most likely mechanism of resistance. Fosmidomycin is a 
phosphonic acid (Fig. 1 A), a charged compound which does 
not readily cross membranes by diffusion but requires transport. 
Cellular membranes therefore represent a barrier to the drug, 
and numerous membranes separate the target enzyme in the 
lumen of the apicoplast from the drug in the medium. These 
include four apicoplast membranes, the parasite plasma mem-
brane, the parasitophorous vacuole (note that this membrane 
typical of apicoplast proteins (see multiple sequence alignment 
in Fig. S3). The extended coding sequence was engineered 
into an epitope tagging construct and transformed into para-
sites. The tagged protein localized to the apicoplast as judged 
by immunofluorescence staining (Fig. 3 A). Using the strategy 
outlined in the previous section for the LytB gene, we engi-
neered a conditional mutant of the DOXPRI gene (Fig. 3, 
note that we constructed the mutant using an untagged regu-
lated  copy).  Successful  gene  targeting  was  confirmed  by 
Southern blot analysis (Fig. 3 B and Fig. S2 B). We demon-
strated tight regulation of the transgene using an antibody 
raised against recombinant protein expressed in E. coli. Next, 
we studied the impact of this mutation on parasite infection. 
We found a pronounced growth defect indistinguishable from 
the phenotype observed for the LytB mutant. Collectively, 
these observations strongly suggest that the entire apicoplast 
DOXP pathway is required for growth and that fosmidomycin 
resistance in T. gondii is not the result of a metabolic shunt that 
sidesteps the target DOXPRI.
Dependence on a target enzyme with known fosmidomycin 
sensitivity does not confer sensitivity to the parasite
We next considered that the T. gondii DOXPRI enzyme itself 
may be inherently resistant to fosmidomycin. We expressed var-
ious portions of the T. gondii DOXPRI gene in E. coli. This re-
sulted in robust production of recombinant protein; however, 
the proteins were largely insoluble and we did not detect sig-
nificant enzymatic activity. Our inability to directly measure 
T. gondii DOXPRI led us to design an indirect experiment. We 
wondered if dependence on an enzyme known to be sensitive 
would render the parasite susceptible. We chose the well charac-
terized DOXPRI from E. coli. The IC50 value of fosmidomycin 
for this enzyme is 8.2 nM, which is slightly below that of the   
P . falciparum homologue (Kuzuyama et al., 1998). We introduced 
the coding sequence of DOXPRI amplified from E. coli into a 
parasite expression construct that fused it with an apicoplast 
leader sequence and a Ty-1 epitope tag. As a control, we also 
engineered the T. gondii DOXPRI gene with a Ty-1 tag. These 
plasmids were introduced into the DOXPRI mutant. As   
shown in Fig. 4 (A and B), the bacterial protein localizes to the 
apicoplast and the protein is proteolytically processed as expected. 
We established by Western blot that under ATc the transgenic   
E. coli protein is the only detectable DOXPRI enzyme in the 
DOXPRI+EcDOXPRI parasite strain (Fig. 4 B). Next, we 
scored the impact of ATc and/or fosmidomycin on the growth 
of this strain in comparison with the mutant and the homolo-
gously complemented line. Plaque assays under ATc revealed that 
the E. coli enzyme fully rescues the mutant, as does the parasite 
enzyme (Fig. 4 D). This strongly supports our initial assumption 
that gene TGGT1_125270 encodes a DOXPRI. Importantly, 
however, both strains remain resistant to fosmidomycin. This   
suggests that fosmidomycin resistance in T. gondii does not   
depend on inherent resistance of the target enzyme. We   
acknowledge that we have not formally established that T. gondii  
DOXPRI is drug sensitive, but we note that even when the para-
site depends on a sensitive enzyme it is still drug resistant.
Figure 4.  Reliance of E. coli DOXPRI does not render T. gondii sen-
sitive to fosmidomycin. (A) Immunofluorescence assay showing the 
localization of Ty-1–tagged E. coli DOXPRI fused to an apicoplast leader 
(green, L-EcDOXPRI). The apicoplast protein Cpn60 is shown for compari-
son (blue). (B and C) Western blot analysis of the DOXPRI mutant com-
plemented with L-EcDOXPRI (B) or an ectopic copy of the coding 
sequence of the T. gondii enzyme under the control of a constitutive pro-
moter (TgDOXPRI; C). In B, blots were probed with the Ty-1 antibody or 
the T. gondii DOXPRI antibody. Note that under ATc only the E. coli enzyme 
is detectable. (D) Plaque assays of the conditional DOXPRI mutant without 
complementation (top), complemented with the E. coli enzyme (middle), 
or complemented with the T. gondii enzyme (bottom). Cultures were 
grown for 10 d in the absence or presence of 0.5 µg/ml ATc and 100 µM 
fosmidomycin as indicated.1552 Fosmidomycin resistance in Toxoplasma gondii | Nair et al.
erythrocytic cycle cannot be propagated in culture). Again 
cellular development appears normal except for a loss of api-
coplast elongation and division (Fig. 5 D). To quantify the 
effect of fosmidomycin on P. berghei parasites in the liver 
stage, we cultured drug treated and control parasites for 65 h, 
which normally results in the production of merosomes—
groups of merozoites which are packaged in liver cell mem-
brane and released. Merosomes represent successful completion 
of the liver stage of the P. berghei life cycle. Fosmidomycin 
treatment significantly and reproducibly reduced the number 
of merosomes (Fig. 5 E), presumably because of the retarded 
growth of the apicoplast. Plasmodium parasites are thus also 
sensitive  to  fosmidomycin  when  developing  in  nucleated 
liver cells just as they are in RBCs.
Compound penetration into mammalian cells can be 
enhanced by masking polar groups with a hydrophobic ester (Li 
et al., 1997). After crossing the membrane, the ester is cleaved 
by cellular esterases, thus releasing the original compound in 
the cytoplasm. We have synthesized several such ester deriva-
tives for fosmidomycin (see Materials and methods for detail). 
We tested the effects of varied concentrations of diphenyl-, 
dimethoxyphenyl-, and dipyvaloxymethyl-fosmidomycin on 
the growth of T. gondii and note that as fosmidomycin these 
derivatives are poor parasite inhibitors, showing essentially no 
activity at the concentrations used (Table S1). Fosmidomycin 
esterification does not provide enhanced efficacy, and this is 
consistent with the host cell membrane not acting as the main 
barrier to drug uptake.  We note that we do not directly demon-
strate enhanced host cell uptake for these compounds.
is thought to contain pores permeable to small molecules), 
and the plasma membrane of the host cell. We performed a 
series of experiments to establish the relative importance of 
each of these potential parasite and host barriers.
The host cell is not the critical determinator of parasite 
fosmidomycin sensitivity
Fosmidomycin-sensitive  apicomplexans  parasitize  erythro-
cytes, and the permeability of the host cell membrane may 
govern fosmidomycin sensitivity (Seeber and Soldati-Favre, 
2010). Plasmodium and Babesia massively reorganize the eryth-
rocyte, a process which includes the installation of new per-
meability pathways in the host cell membrane (Desai et al., 
1993; Alkhalil et al., 2007). These pathways dramatically change 
the rate of metabolite uptake and may be required for fosmid-
omycin transport. This hypothesis makes testable predic-
tions: first, that sensitivity depends on the erythrocyte and its 
remodeling in sensitive species; and second, that breaching 
the host cell permeability barrier will produce sensitivity in 
resistant species.
To explore the first prediction, we conducted experi-
ments with the rodent malaria model Plasmodium berghei dur-
ing infection of liver cells. Treating parasites at liver stage 
with 10 µM fosmidomycin produced a distinct cellular phe-
notype in which overall cellular development appears normal 
but the development of the apicoplast is blocked (Fig. 5 B). This 
mirrors the response P. falciparum parasites show to fosmido-
mycin treatment in the blood stage (please note that we use   
P. falciparum for comparison in this study because the P. berghei 
Figure 5.  Fosmidomycin affects Plasmodium berghei 
apicoplast liver cell development and merosome  
formation. (A and B) Immunofluorescence assay of  
P. berghei–infected liver cells. Apicoplast (red) labeled with 
anti-ACP antibody, parasite (green) labeled with antibody 
raised to whole P. berghei parasites, and DNA labeled with 
DAPI are shown. Underdeveloped apicoplast is highlighted 
by the white arrowhead. Note that this phenotype mirrors 
the effect of other drugs targeting the apicoplast in liver 
stages (Friesen et al., 2010). (C and D) Live cell images of  
P. falciparum–infected erythrocytes. Cells shown harbor 
parasite schizonts expressing RFP localized to the apico-
plast (red), and nuclei are stained with Hoechst 33342 
(blue). The underdeveloped apicoplast is indicated by a 
white arrowhead. (E) P. berghei liver stage development as 
measured by the production of merosomes. Treatment 
with10 µM fosmidomycin reduces successful completion 
of liver stage infection to 55.8% of untreated control. 
Mersome counts were conducted on pairwise samples. 
Treatment and control well were infected from a pooled 
sporozoite preparation to ensure uniformity. Note that 
absolute merosome numbers vary between biological 
replicates (79–458 for the untreated control); however, 
the relative level of reduction caused by fosmidomycin 
treatment is highly consistent (error bar indicates stan-
dard deviation, n = 9 independent experiments; ***, P < 
0.0001, paired Student’s t test).JEM Vol. 208, No. 7 
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the expression of heterologous transgenes in T. gondii; Striepen 
and Soldati, 2007). L-GlpT and the SP-GlpT show a similar 
immunofluorescence pattern: the protein is present in various 
parasite membranes including the plasma membrane (Fig. 6, 
A and B). We also detect more intense internal staining close to 
the nucleus. Colabeling with an anti-Cpn60 antibody shows that 
this staining does not coincide with the apicoplast (Fig. 6 C).
We tested the growth of GlpT-expressing parasites in the 
presence of varied concentrations of fosmidomycin (0.375–
100  µM).  To  facilitate  such  measurements,  we  had  con-
structed the GlpT-expressing strains in a fluorescent parasite 
line. Parasites stably expressing L-GlpT or SP-GlpT were sen-
sitive to fosmidomycin with IC50 values of 1.3 µM (L-GlpT) 
and 2.6 µM (Sp-GlpT), respectively (Fig. 7, B and C; and 
see the plaque assay in Fig. S4). These values are similar to 
those previously reported for different Plasmodium and Babesia 
species and at least 100-fold lower than those observed with 
the RH-YFP-YFP parental strain. Note that because of the 
strong drug resistance we were unable to establish a precise 
IC50 for wild-type cells. To establish whether fosmidomycin 
sensitivity in GlpT transgenic parasites is directly dependent 
on the transport activity of GlpT, we constructed two GlpT 
mutants. G3P is thought to bind to two critical arginine resi-
dues at positions 45 and 269 that are exposed during substrate 
loading (Huang et al., 2003). Upon G3P binding, the protein 
changes conformation in a rocker switch–type movement 
that results in translocation of the substrate. Mutations of 
these residues affect binding and transport of G3P (Law et al., 
2008). We engineered an R45K and an R45K-R269K dou-
ble replacement into L-GlpT by site-directed mutagenesis that 
were introduced into YFP-expressing parasites. Mutant pro-
teins were expressed with localization and expression level 
equivalent to the L-GlpT strain as judged by immunofluo-
rescence and Western blot (Fig. 7 F and Fig. S5). Parasites   
expressing the single mutant showed a fourfold drop in 
fosmidomycin sensitivity when compared with L-GlpT para-
sites (IC50 = 5.7 µM), whereas those carrying the double mu-
tant were fully resistant to fosmidomycin (Fig. 7, D and E). 
We conclude that expression of the bacterial GlpT confers a 
dramatic increase in fosmidomycin sensitivity. Sensitivity de-
pends on transporter activity but appears not to require api-
coplast localization of the protein.
We next tested esterified fosmidomycin analogues against 
the L-GlpT line and again established IC50 values (Table S1). 
The IC50 values for diphenyl- and dimethoxyphenyl-fosmido-
mycin were indinstinguishable from those for underivatized 
fosmidomycin (1 and 2 µM, respectively). Dipyvaloxymethyl-
fosmidomycin shows poor efficacy in wild type and transgen-
ics. Esterification thus did not produce enhancement beyond 
the dramatic effect of GlpT expression. Collectively, our re-
sults indicate that the parasite, and not the host, represents the 
main barrier to fosmidomycin. To ensure that our conclu-
sion is not limited to our tissue-cultured human fibroblasts, 
we conducted in vivo experiments (Fig. 7 G). Webster mice   
were infected with 20 L-GlpT expressing T. gondii by intra-
peritoneal injection in two groups of five. One group of 
Expression of a bacterial transporter confers drug sensitivity 
to T. gondii
We next hypothesized that T. gondii may be unable to take up 
fosmidomycin, or alternatively that the T. gondii apicoplast 
lacks an import mechanism for the drug from the parasite   
cytoplasm. As the lack of import is difficult to demonstrate in 
absence of a positive control, we thought to artificially engi-
neer transport and sensitivity. The sensitivity of a variety of 
bacterial pathogens to fosmidomycin, and the structurally re-
lated antibiotic fosfomycin, depends on the glycerol-3-phosphate 
(G3P) transporter (GlpT; Sakamoto et al., 2003; Takahata et al., 
2010). This transporter facilitates the uptake of sn-G3P in ex-
change for inorganic phosphate (Law et al., 2009). We ampli-
fied the coding sequence for GlpT from E. coli and engineered 
three parasite expression vectors: the first construct added the 
full leader of the apicoplast protein FNR at the N terminus of 
GlpT (L-GlpT), the second used only the N-terminal signal 
peptide portion (SP-GlpT), and the third did not add any se-
quences at the N terminus. All these versions carried a Ty-1 
epitope. We were able to establish parasite lines expressing the 
first two transporter versions but did not detect GlpT in the 
absence of an N-terminal fusion (fusion is known to enhance 
Figure 6.  Expression of the E. coli GlpT. Immunofluorescence staining 
of Ty-1–tagged E. coli GlpT (red) in parasites expressing the transporter fused 
downstream of the full apicoplast leader peptide of FNR (L-GlpT; A and C) or 
the signal peptide portion of the leader (SP-GlpT; B). These strains were con-
structed in a YFP-expressing parasite, and YFP and DAPI are shown to indi-
cate nucleus and cytoplasm, respectively. Note that the internal staining is 
distinct from the apicoplast labeled with an antibody to Cpn60 (blue, C). 
Insets in C show the apicoplast at higher magnification (200%).1554 Fosmidomycin resistance in Toxoplasma gondii | Nair et al.
untreated mice died after 10 d. Treated mice did not show 
any signs of disease for the observation period of 30 d. West-
ern blot analysis of sera drawn from treated mice indicated 
that mice were successfully infected. The trial was repeated 
with three mice in each group with similar outcome (note 
that the amount of available drug limited the group size). 
We conclude that fosmidomycin treatment for 10 d cures 
mice from a lethal challenge infection of GlpT-expressing 
RH strain parasites.
GlpT expression enables uptake of fosmidomycin  
in transgenic parasites
We next asked whether fosmidomycin sensitivity in GlpT-
expressing parasites is a result of increased drug uptake. To 
test this, we used growth inhibition of E. coli as a simple but 
sensitive bioassay for fosmidomycin. By exposing the bacteria 
to parasite lysate in a classical agar plate diffusion assay, we 
would determine if parasites had taken up fosmidomycin. 
Wild-type parasites and our transgenic lines expressing GlpT 
were exposed to fosmidomycin, and parasites were harvested 
by centrifugation, washed, and disrupted by sonication. The 
parasite lysate was loaded onto paper discs and these were 
layered on agar plates inoculated with E. coli. Bacteria were 
then allowed to grow for 24 h. Fig. 8 A shows discs impreg-
nated with known amounts of fosmidomycin. The bacterio-
cidal activity of the drug is visible as clear zones of inhibition 
against an opaque bacterial lawn. The diameter of these zones 
is proportional to the amount of drug, and we established a 
standard curve from 1 to 200 ng. We next compared wild-
type parasites (RH) with the GlpT transgenic lines (Fig. 8 B). 
Although we detect no fosmidomycin in RH wild type   
(<1 ng/107 cells), we note robust inhibition zones in the GlpT-
expressing parasites equivalent to 28 and 23.4 ng for L-GlpT 
and Sp-GlpT, respectively. Intracellular fosmidomycin con-
centrations were reduced in parasites expressing the trans-
porter with the single R45K mutation (10.4 ng) and were 
equivalent to untransfected parasites in those expressing the 
R45K-R269K double-mutant transporters (Fig. 8 D). We 
conclude that wild-type T. gondii are incapable of accumulat-
ing fosmidomycin and that expression of GlpT enables robust 
drug uptake.
Permeabilizing the parasite plasma membrane removes  
a significant barrier for fosmidomycin
We conducted additional experiments to biochemically de-
fine the parasite barrier to fosmidomycin flux and its breach 
by GlpT. Work on organellar tRNAs of T. gondii has demon-
strated dramatic differences in the detergent sensitivity of the 
plasma membrane and the membranes of the apicoplast (Esseiva 
et al., 2004). Cytoplasmic tRNAs were susceptible to RNase 
digestion after treatment with 0.1% digitonin, whereas apico-
plast tRNAs remained protected. Although it is technically 
challenging to measure uptake in the presence of detergent, 
measuring release from parasites is feasible using the assay we 
developed. We incubated wild type and L-GlpT–expressing 
parasites with fosmidomycin. Next, we exposed parasites to 
mice was treated with a daily injection of 100 mg/kg fosmido-
mycin in PBS for 10 consecutive days, and a second group was 
mock treated with PBS alone. The GlpT transgenic parasite 
line is derived from the highly virulent type I strain RH, and 
Figure 7.  The GlpT confers fosmidomycin sensitivity to T. gondii.  
(A–E) Fluorescence assays measuring the growth of RH-YFP-YFP parasite 
(A) and transgenic clones derived from this line expressing L-GlpT (B),  
SP-GlpT (C), and two point mutants of L-GlpT R45K (D) or R45K-R269K  
(E). Assays were conducted using a serial dilution series of fosmidomycin 
from 100–0.375 µM, and IC50 values were calculated based on growth at 
day 4. Only three drug concentrations are shown here for simplicity: 0 µM 
(squares), 3.1 µM (triangles), and 100 µM (circles). Data points reflect the 
mean of duplicate wells and error bars show standard deviation. Where 
no bar is shown it was smaller than the symbol. (F) Western blot analysis 
using the anti–Ty-1 antibody indicates a comparable level of GlpT expres-
sion in all lines, and -tubulin serves as loading control. (G) Mice were 
infected with 20 L-GlpT parasites each. Infected mice were treated once 
daily for 10 d (open symbols). Control mice were mock treated (closed 
symbols), and percentage of survival is shown for both groups. The trial 
was conducted with five mice in each group (circles) and repeated inde-
pendently with three mice per group (squares). All untreated mice were 
dead by day 13, and treated mice showed no sign of disease.JEM Vol. 208, No. 7 
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of fosmidomycin does not produce an inhibition zone. To con-
trol for the membrane specificity of digitonin, we evaluated a 
parasite line that expresses  YFP in the cytoplasm and RFP in the 
apicoplast by fluorescence microscopy and flow cytometry. Fig. 8 
(G and H) shows that digitonin-treated parasites loose cyptoplas-
mic YFP while maintaining red fluorescence in the plastid. We 
note that the majority of fosmidomycin can be released by 
specific permeabilization of the parasite plasma membrane.
0.1% digitonin for 5 min on ice followed by centrifugation to 
separate the detergent extract from the cell pellet, which includes 
the apicoplast. Residual cells in the pellet were then broken as 
described in the previous section, and we measured the fosmido-
mycin concentration in both fractions using the bioassay. As 
shown in Fig. 8 (E and F), digitonin treatment released 17.6 ng, 
or 86% of the total parasite-associated fosmidomycin from the 
L-GlpT parasites. Note that digitonin treatment in the absence 
Figure 8.  GlpT expression enables fosmidomycin accumulation in transgenic parasites. (A) Bioassay to measure the amount of fosmidomycin 
using E. coli. Note clear inhibition zones against opaque bacterial lawn. (C) Diameter of inhibition zones for a series of known amounts of fosmidomycin 
was used to establish a standard curve. (B) The indicated parasite strains were exposed to 100 µM fosmidomycin and the amount of fosmidomycin taken 
up by each strain was measured by bioassay. (D) Inhibition zones were measured and transformed into drug amounts using the standard curve shown in C. 
Note that the robust fosmidomycin uptake in GlpT-expressing parasite was absent in RH and the R45K-R269K mutant. (E) Parasites were exposed to 
fosmidomycin as in B and treated with 0.1% digitonin before centrifugation into extract and cell pellet. Fosmidomycin was measured in both fractions by 
bioassay, and F shows a quantitative analysis of these experiments (data points and bars in C, D, and F show the means of duplicate experiments and 
standard deviation as error bar). (G and H) A parasite strain that expresses YFP-YFP in the cytoplasm (green) and RFP in the apicoplast (red) was used to 
assess the specificity of the digitonin treatment by live cell fluorescence microscopy (G) and flow cytometry (H). Note that the small difference in the red 
channel between red only and red and green parasites is a result of compensation. (C, D, and F) Data points reflect the mean of duplicate wells and error 
bars show standard deviation. Where no bar is shown it was smaller than the symbol.1556 Fosmidomycin resistance in Toxoplasma gondii | Nair et al.
Fosmidomycin uptake governs parasite sensitivity
In the current study, we have tested a series of mechanisms 
potentially underlying fosmidomycin resistance in T. gondii. 
We did not find direct evidence for redundancy as a result of 
product salvage, metabolic shunting of the target, or inherent 
drug resistance of the target enzyme. A recent study in P. falci-
parum has shown that fosmidomycin resistance induced by in 
vitro selection was associated with copy number variation of 
the gene encoding the target enzyme (Dharia et al., 2009). It 
is conceivable that T. gondii also overexpresses DOXPRI and 
that this confers resistance, but we deem this unlikely. Over-
expression in Plasmodium conferred a relatively modest eight-
fold increase in the IC50, whereas the difference in sensitivity 
between Plasmodium and T. gondii is several 100-fold. Overall, 
our data are most consistent with a lack of drug access as the 
primary  mechanism  of  insensitivity.  The  key  observations 
supporting this hypothesis are: (1) that we fail to detect drug 
uptake in wild-type tachyzoites (Fig. 8), and (2) that we can 
render parasites drug sensitive by engineering uptake using a 
fosmidomycin transporter. Expression of this transporter re-
duces the IC50 >100-fold to 1.5 µM, a value comparable to 
sensitive  species.  Furthermore,  we  demonstrate  that  these 
transgenic parasites now accumulate fosmidomycin and that 
point mutations that attenuate transport also attenuate drug 
efficacy. Lack of uptake has also been described as a major 
mechanism for fosmidomycin resistance in bacteria. This   
includes natural resistance as documented for Mycobacterium 
(Dhiman et al., 2005; Brown and Parish, 2008) as well as ac-
quired resistance in response to drug pressure (Sakamoto et al., 
2003; Takahata et al., 2010). Loss of drug import is therefore 
a potential threat to the clinical use of fosmidomycin as an   
antimalarial. That loss of the transporter was not readily observed 
in resistant malaria parasite (Dharia et al., 2009) may indicate 
that the transporter is essential and therefore not as easily lost 
as it is in bacteria. Understanding the true metabolic function 
of the transporter will help to gauge the probability of its loss 
and the development of resistance. Alternatively, identifying 
DOXP pathway inhibitors that do not require a specific trans-
porter to reach the target could circumvent this issue. Such 
inhibitors should also show broader efficacy against other api-
complexans. Most of the DOXP pathway intermediates are 
highly charged compounds, and thus many of the inhibitors 
identified so far are charged as well. However, there are ex-
ceptions, like the herbicide ketoclomazone, an inhibitor of 
DOXP synthase which has recently been found to have anti-
bacterial activity (Matsue et al., 2010).
What governs fosmidomycin uptake?
Why do only some apicomplexan parasites take up fosmido-
mycin? Our results support a model in which the parasite 
plasma membrane of Plasmodium has fosmidomycin transport 
activity that appears to be absent or diminished in T. gondii. 
This hypothetical transporter likely imports metabolites from 
the host cell, and fosmidomycin hitches a ride as an uninvited 
and deadly passenger. As demonstrated by GlpT, G3P is a 
strong (but likely not the only) potential candidate for such a 
DISCUSSION
The apicoplast has several attractive attributes for drug devel-
opment. It is home to literally hundreds of proteins, many of 
which are enzymes, and many of these enzymes can be inhib-
ited using drug-like small molecules (Wiesner et al., 2008). 
There are established targets among the enzymes that repli-
cate, transcribe, and translate the apicoplast genome (Dahl and 
Rosenthal, 2008), and some of these (azithromycin or tetra-
cycline) are already in clinical use for toxoplasmosis or malaria.
The DOXP pathway is a good target for the development  
of antiparasitic drugs
A second important group of potential targets is enzymes 
central to apicoplast anabolism, in particular the FASII and 
DOXP pathways for the synthesis of fatty acids and iso-
prenoid precursors, respectively. These enzymes are of cya-
nobacterial origin, and their pronounced evolutionary and 
mechansistic divergence from those used by the human host 
offers  the  potential  of  specificity.  Significant  efforts  have 
been made to characterize the enzymology of both path-
ways and to discover, and iteratively optimize, inhibitors. As 
discussed in more detail in the introduction, the example of 
the FASII pathway argues for the rigorous analysis not only 
of the diversity and drugability of the chosen target but also 
of its essentiality. Essentiality is a complex phenomenon, 
and, surprisingly, pronounced differences are found among 
Apicomplexa depending on the parasite species, the life   
cycle stage, and the host cell niche occupied by that stage. 
There is pharmacological support for a critical role of the 
DOXP pathway for Plasmodium and Babesia, yet many other 
Apicomplexa are resistant to fosmidomycin. In this study, 
we provide evidence that a functional DOXP pathway is an 
absolute requirement for the growth and survival of T. gondii 
despite the parasite’s resistance to fosmidomycin. We engi-
neered conditional null mutants for an early and a late en-
zymatic step in the pathway, and both mutants are lethal. We 
note in this paper that growth ceases very rapidly upon 
down-regulation of these conditional alleles. As shown in 
Fig. S6, the kinetics of inhibition are faster than those of loss 
of FASII and similar to those obtained by ablation of the 
APT (Brooks et al., 2010). Our experiments argue that the 
DOXP pathway represents a valid target across the phylum. 
They also support the notion of isoprenoid precursor syn-
thesis as a key function of the apicoplast. Although it is now 
clear that IPP production in the apicoplast is essential, it is 
less clear why. Numerous potential functions of IPP-derived 
molecules have been discussed. They may be apicoplast spe-
cific  (ispoprenylation  of  tRNAs),  act  in  other  organelles 
(providing dolichol or ubiquinone to the parasite ER or the 
mitochondrion, respectively), or more broadly control para-
site behavior and development (abscisic acid and other iso-
prenoid plant hormones; Moreno and Li, 2008). The mutants 
established in this study provide an excellent starting point 
to uncover the most critical metabolite and its function for 
the parasite. Uncovering this function may lead to addi-
tional targets.JEM Vol. 208, No. 7 
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Genetic manipulations. 5 RACE PCR experiments were performed using 
the RACE kit (BD). Fig. S1 shows a detailed schematic overview of the   
genetic manipulations used and Tables S2, S3, and S4 provide all primers 
used. The validated or corrected coding sequences were amplified and intro-
duced into plasmid pDT7S4myc3 (see Tables S2 and S3 for specific primers 
and restriction sites), placing them under the control of a tet-regulated pro-
moter as detailed previously (Brooks et al., 2010). Clonal lines were estab-
lished in a transactivator strain (Meissner et al., 2002) by transfection and 
pyrimethamine selection. Gene-targeting constructs were derived from cos-
mid PSBLA92 (LytB) or TOXP686 (DOXPRI) by recombineering in E. coli 
EL250 (Brooks et al., 2010). These modified cosmids were then used to dis-
rupt the native loci by double homologous recombination and replacement 
of the entire coding region with chloramphenicol acetyl transferase, and stable 
clones were derived by chloramphenicol selection. Deletion was confirmed 
by PCR and Southern blotting. Genomic parasite DNA was restricted as in-
dicated, separated on 0.7% agarose gels, and transferred to nylon membrane. 
Probe DNA was prepared by PCR (Fig. S2 provides maps indicating the po-
sitions of probes and restriction sites) and 32P labeled by random priming. For 
complementation analysis, coding sequences were introduced into plasmid 
pBTTy placing them under control of the constitutive tubulin promoter 
(Brooks et al., 2010) and stable transformants were established by phleomycin 
selection (Soldati et al., 1995). To facilitate fluorescence growth assays, paren-
tal, mutant, and complemented lines were transfected with plasmid PCTR2T 
(van Dooren et al., 2008). Red fluorescent parasites expressing tandem   
tomato RFP were isolated by cell sorting using a MoFlo sorter (Dako).
Expression of T. gondii DOXPRI in E. coli. The coding sequence for 
DOXPRI lacking the presumptive leader and transit peptide (aa 187–632) 
was cloned into expression plasmid pAVA0421, and the construct was intro-
duced into E. coli BL21. Recombinant protein was purified under denatur-
ing conditions and used to immunize rabbits (Cocallico Biologicals). We also 
expressed T. gondii DOXPRI (either aa 187–632 or aa 20–632) fused to the 
C terminus of maltose binding protein (New England Biolabs, Inc.). Enzy-
matic activity of purified MBP-TgDOXPRI was measured after the oxida-
tion of NADPH to NADP+ (Dhiman et al., 2005). We did not detect 
activity for the T. gondii recombinant enzyme but noted robust activity for the 
E. coli enzyme expressed in parallel.
Expression of E. coli DOXPRI in T. gondii. We engineered a plasmid 
to target heterologous proteins to the apicoplast using the leader sequence of 
T. gondii ferredoxin NADP reductase (FNR, aa 1–150) and a Ty-1 epitope 
(pBTTYFNRL). We amplified the coding sequence of E. coli DOXPRI 
(AP000833)  from  strain  DH5  and  introduced  it  into  pBTTYFNRL. 
DOXPRI parasites were transfected with the resulting plasmid and stable 
transformants were selected using phleomycin.
Expression of E. coli GlpT in T. gondii. The coding sequence of the E. coli 
GlpT (NP416743) was amplified and cloned in frame with the full apicoplast 
leader sequence of FNR (pBTTYFNRLE.c.GlpT) or the signal sequence 
portion (pBTTYFNRSPE.c.GlpT). Point mutantions were introduced using 
QuickChange site-directed mutagenesis (Agilent Technologies). Mutagenesis 
was performed in plasmid PCR2.1-GlpT. Mutagenic primers were designed 
to introduce arginine to lysine changes (ACG to AAA) in GlpT at positions 
45 and 269. Mutations were confirmed by sequencing and modified coding 
sequences were introducted into pBTTYFNRL.
Immunofluorescence  and  Western  blotting.  Immunofluorescence  and 
Western assays were performed as described previously (Brooks et al., 2010). 
Primary antibodies were were used at 1:100 (c-myc; Roche), 1:5 (Ty-1; K. Gull, 
Oxford University, Oxford, England, UK), and 1:1,000 (anti–T. gondii  
DOXPRI, ACP [Waller et al., 1998], and Cpn60). Slides were viewed on a 
DMIRBE (Leica) or a DeltaVision microscope (Applied Precision). Images were 
captured, deconvolved, and adjusted for contrast using Openlab, Volocity, or Soft-
worx software (PerkinElmer or Applied Precision). For Western blots, primary 
antibodies were used at 1:100 (c-myc), 1: 2,500 (anti-DOXPRI), or 1:10 (Ty-1).
metabolite. In E. coli, imported G3P serves as a major source 
of carbon and energy but also supplies glycerophospholipid 
synthesis (Huang et al., 2003). The demand for glycerophos-
pholipids of Plasmodium in the RBC is very heavy and met by 
a complex web of pathways using elements of salvage and de 
novo synthesis (Déchamps et al., 2010). Plasmodium can syn-
thesize G3P through a glycerol kinase, for example; however 
this enzyme is poorly expressed and not essential during RBC 
development, arguing for additional sources (Schnick et al., 
2009). The next downstream step is the acylation of G3P. 
Interestingly, both Plasmodium and T. gondii encode two en-
zymes for the initial sn-1 reaction, one localized to the ER 
and one to the apicoplast (Déchamps et al., 2010). Consump-
tion of G3P in the apicoplast could require G3P import, and 
the yet-to-be-identified plastid GlpT may be the route that 
fosmidomycin takes to its target in the apicoplast lumen. Our 
uptake studies (Fig. 8) argue that in T. gondii the plasma 
membrane, and most likely not the apicoplast membrane, is 
the impediment for fosmidomycin. This would fit the shared 
distribution of G3P acyl transferases. The activity of G3P 
dehydrogenase provides an alternative route to G3P from   
dihydroxyacetone-phosphate. Both Plasmodium and T. gondii 
encode two genes and, at least in the case of Plasmodium, one 
of the proteins carries a signal peptide that could hint apico-
plast localization (Ralph et al., 2004). In that case, there may 
not be need for G3P import into the apicoplast, as triose 
phosphates are plentiful as a result of the activity of the APT. 
Detailed biochemical experiments are needed to penetrate 
the complexity of these metabolic pathways. Metabolomic 
studies tracing stable isotope labeled G3P in different Api-
complexa could offer a way to further evaluate the model. In 
summary, our analysis of fosmidomycin sensitivity in T. gon-
dii and Plasmodium has validated the target DOXPRI, has 
pointed out potential mechanisms of resistance, and has gen-
erated testable hypotheses and reagents to further dissect the 
metabolic basis of apicoplast function and drug sensitivity.
MATERIALS AND METHODS
Parasite culture and growth assays. RH strain T. gondii tachyzoites were 
maintained in human fibroblasts and genetically manipulated as detailed pre-
viously (Striepen and Soldati, 2007). Parasite growth was measured by 
fluorescence assay (Gubbels et al., 2003). This assay quantifies parasite fluo-
resecence daily for a week in a 96-well format. Parasites are fluorescent because 
of expression of either a tandem YFP (Fig. 1 and 7) or a tandem tomato RFP 
(Fig. 2 and 3) transgene. Drug assays were performed by twofold serial dilu-
tions of drug using concentrations ranging from 100 to 0.375 µM. IC50  
values were calculated with Prism software (GraphPad Software) using a 
nonlinear dose-response curve to fit normalized fluorescence values from 
day 4 (the phase of exponential growth). Fosmidomycin was provided by   
H. Jomaa (Institut für Klinische Chemie und Pathobiochemie, Justus-Liebig-
Universität Giessen, Giessen, Germany and Y. Song). All experiments were 
conducted at least in duplicate.
Coverslip cultures were seeded with HepG2 cells and infected with   
P . berghei ANKA sporozoites dissected from the salivary glands of infected 
Anopheles stephensi (Schmidt-Christensen et al., 2008). 10 µM fosmidomycin 
was added to the media 12 h after infection and medium was changed every 
24 h. Infected cells were incubated at 37°C and 8% CO2 until fixation for 
IFA (50 h after infection) or until infected cells detached and formed mero-
somes (65 h).1558 Fosmidomycin resistance in Toxoplasma gondii | Nair et al.
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